Biomedical Engineering Reference
In-Depth Information
Presnell, S.R., O'Hara, P.J., Hagen, F.S., Roth, G.J., and Foster, D.C. 1994. Cloning and expression of murine
thrombopoietin cDNA and stimulation of platelet production
in vivo
.
Nature
369
, 565-568.
Markham, A. and Bryson, H. 1995. Epoetin alfa, a review of its pharmacodynamic and pharmacokinetic
properties and therapeutic use in non-renal applications.
Drugs
49
(2), 232-254.
Miyazaki, H. and Kato, T. 1999. Thrombopoietin: biology and clinical potential.
International Journal of
Haematology
70
(4), 216-225.
Ogden, J. 1994. Thrombopoietin - the erythropoietin of platelets?
Trends in Biotechnology
12
, 389-390.
Strauss, R. 2006. Controversies in the management of the anemia of prematurity using single-donor red blood cell
transfusions and/or recombinant human erythropoietin.
Transfusion Medicine Review
20
(1), 34 - 44.
Colony-stimulating factors
Duarte, R. and Frank, D. 2002. The synergy between stem cell factor (SCF) and granulocyte colony stimulating
factor (G-CSF): molecular basis and clinical relevance.
Leukaemia and Lymphoma
43
(6), 1179-1187.
Esser, M. and Brunner, H. 2003. Economic evaluations of granulocyte colony stimulating factor in the prevention
and treatment of chemotherapy-induced neutropenia.
Pharmacoeconomics
21
(18), 1295-1313.
Fleetwood, A.J., Cook, A.D., and Hamilton, J.A. 2005. Functions of granulocyte-macrophage colony stimulating
factor.
Critical Reviews in Immunology
25
(5), 405-428.
Frampton, J.E., Lee, C.R., and Faulds, D. 1994. Filgrastim. A review of its pharmacological properties and
therapeutic effi cacy in neutropenia.
Drugs
48
(5), 731-760.
Frampton, J.E., Yarker, Y.E., and Goa, K.L. 1995. Lenograstim. A review of its pharmacological properties and
therapeutic effi cacy in neutropenia and related clinical settings.
Drugs
49
(5), 767-793.
Hamilton, J. 1997. CSF-1 signal transduction.
Journal of Leukocyte Biology
62
(2), 145-155.
Harousseau, J. 1997. The role of colony-stimulating factors in the treatment of acute leukaemia.
Biodrugs
7
(6),
448-460.
Heuser, M. and Ganser, A. 2005. Colony stimulating factors in the management of neutropenia and its
complications.
Annals of Hematology
84
(11), 697-708.
Lyman, G. and Kuderer, N. 2004. The economics of the colony stimulating factors in the prevention and treatment
of febrile neutropenia.
Critical Review in Oncology and Hematology
50
(2), 129-146.
Tabbara, I.A., Ghazal, C.D., and Ghazal, H.H. 1996. The clinical applications of granulocyte-colony-stimulating
factor in haematopoietic stem cell transplantation: a review.
Anticancer Research
16
(6B), 3901-3905.
Watowich, S.S., Wu, H., Socolovsky, M., Klingmuller, U., Constantinescu, S.N., and Lodish, H.F. 1996. Cytokine
receptor signal transduction and the control of haematopoietic cell development.
Annual Review of Cell and
Developmental Biology
12
, 91-128.
Insulin-like growth factors
Bach, L. 1999. The insulin-like growth factor system: basic and clinical aspects.
Australian and New Zealand
Journal of Medicine
.
29
(3), 355-361.
Furstenberger, G. and Senn, H. 2002. Insulin like growth factors and cancer.
Lancet Oncology
,
3
(5), 298-302.
Kostecka, Z. and Blahovec, J. 2002. Animal insulin-like growth factor binding proteins and their biological
functions.
Veterinarni Medicina
47
(2-3), 75-84.
LeRoith, D. 1997. Insulin-like growth factors.
New England Journal of Medicine
336
(9), 633-640.
Schmid, C. 1995. Insulin-like growth factors.
Cell Biology International
19
(5), 445-457.
Yee, D. 2006. Targeting insulin-like growth factor pathways.
British Journal of Cancer
94
(4), 465-468.
Zumkeller, W. 2002. The insulin-like growth factor system in hematopoietic cells.
Leukaemia and Lymphoma
43
(3), 487-491.
Search WWH ::
Custom Search